Sanofi 4th-qtr profit misses expectations but sales in line

7 February 2018

French pharma major Sanofi (Euronext: SAN) this morning reported that fourth-quarter 2017 business net income fell 10.8% at constant exchange rates to 1.33 billion euros ($1.64 billion), missing the 1.46 billion euros expectations of analysts polled by Reuters in partnership with Inquiry Financial.

Sanofi said it had booked an impairment of 87 million euros related to Dengvaxia, its dengue vaccine currently at the center of a health scare in the Philippines, in the fourth quarter.

Net profit of 129 million euros for the quarter compared with 790 million euros in the like period a year earlier. Total sales rose 4.1% to 8.7 billion euros, in line with analysts’ forecasts.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK